Pharmaniaga Eyes Biopharma Expansion, Logistics Growth After Regularisation Plan
Pharmaniaga’s 9MFY25 results fell short of expectations, recording only 31% of the annual earnings forecast, prompting a revised target price of RM0.30 while maintaining a BUY call. The group’s core PATAMI dropped sharply to RM33.9 million, down 73% year-on-year, mainly due to higher transportation costs for newly added APPL products delivered to East Malaysia via air and sea freight.
Despite this, revenue grew 6% to RM3 billion. The manufacturing division posted stronger profit, supported by rising demand for in-house medicines from government hospitals and ongoing vaccine expansion. Logistics and distribution, however, remained pressured by elevated transport costs and sales of older inventory at revised prices.
In Indonesia, revenue and profit weakened due to currency fluctuations.
Pharmaniaga’s financial position improved significantly following its Regularisation Plan, with cash increasing 418% and borrowings reduced by 24%. The group expects the impact from logistics to ease ahead of biopharmaceutical commercialisation in FY26.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
Saudi Arabia weighs price war or stability after UAE exit from OPEC+, with Malaysia’s O&G…
Advancecon Holdings has secured a RM48 million contract for infrastructure work in Johor, signaling strong…
UAE exit from OPEC+ and USD100 oil boost Malaysia’s energy outlook; Dialog and Hibiscus seen…
Malaysia benefits from high oil prices, but faces inflation and logistical risks due to the…
ASEAN manufacturing PMI falls to six-month low as Middle East war drives price pressures, supply…
FBM KLCI advanced on stronger buying momentum despite global market weakness, rising geopolitical tensions and…
This website uses cookies.